While the overall CD3+ T cell proportion of leukocytes increased following SAR131675 treatment at day 22 (Figure 5C), further analysis showed that only the CD8+ T cell subset significantly increased in the liver, while in the tumor, SAR131675 treatment significantly increased the proportion of the CD4+ T cell subset (Figure 7A). The gene discussed is CD8A; the disease is neoplasm.